Literature DB >> 30426221

Childhood onset steroid-sensitive nephrotic syndrome continues into adulthood.

Trine Korsgaard1, René Frydensbjerg Andersen1, Shivani Joshi2, Søren Hagstrøm3,4, Søren Rittig5.   

Abstract

BACKGROUND: Childhood steroid-sensitive nephrotic syndrome (SSNS) has previously been assumed to be a disease of childhood. This has been challenged by few studies reporting that some patients with childhood SSNS may continue to relapse into adulthood. The aim of this study was to investigate the long-term outcome of childhood SSNS presenting data from an unselected well-defined cohort of Danish patients.
METHODS: We conducted a retrospective study of the clinical outcome from a population of patients consecutively admitted to the pediatric departments in the central and northern region of Denmark from 1998 to 2015. Patients were followed until August 2017. Data were collected from the patient's medical records.
RESULTS: Long-term outcome was studied in 39 adult patients with childhood onset SSNS. A total of 31% (12/39) had active disease in adulthood. Univariate analysis showed that more severe forms of SSNS (e.g., steroid dependent/frequent relapsing (SD/FR) nephrotic syndrome) in childhood were associated with active disease in adulthood. Comparing adult patients with SD/FR showed a significantly higher number of relapses/patient/year from late childhood and adolescence in the group with active disease vs. non-active disease (1.06 (95%CI: 0.32-1.81) vs. 0.19 (95%CI: 0.06-0.31, p = 0.005).
CONCLUSION: In general, one third of all patients with SSNS during childhood continue to have active disease during early adulthood, in particular patients with SD/FR continue to suffer from active disease. The present data illustrates that SSNS is not just a disease of childhood but persists in adulthood in a significant number of patients.

Entities:  

Keywords:  Children; Long-term outcome; Relapse; Steroid-sensitive nephrotic syndrome

Mesh:

Substances:

Year:  2018        PMID: 30426221     DOI: 10.1007/s00467-018-4119-8

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  26 in total

1.  The nephrotic syndrome.

Authors:  Roberto Gordillo; Adrian Spitzer
Journal:  Pediatr Rev       Date:  2009-03

2.  Rituximab for childhood-onset nephrotic syndrome.

Authors:  Elisabeth M Hodson; Jonathan C Craig
Journal:  Lancet       Date:  2014-06-22       Impact factor: 79.321

3.  HLA-DQA1 and APOL1 as Risk Loci for Childhood-Onset Steroid-Sensitive and Steroid-Resistant Nephrotic Syndrome.

Authors:  Adebowale Adeyemo; Christopher Esezobor; Adaobi Solarin; Asiri Abeyagunawardena; Jameela A Kari; Sherif El Desoky; Larry A Greenbaum; Margret Kamel; Mahmoud Kallash; Cynthia Silva; Alex Young; Tracey E Hunley; Nilka de Jesus-Gonzalez; Tarak Srivastava; Rasheed Gbadegesin
Journal:  Am J Kidney Dis       Date:  2017-12-23       Impact factor: 8.860

4.  Time trends and ethnic patterns of childhood nephrotic syndrome in Yorkshire, UK.

Authors:  P A McKinney; R G Feltbower; J T Brocklebank; M M Fitzpatrick
Journal:  Pediatr Nephrol       Date:  2001-12       Impact factor: 3.714

5.  Children with steroid-sensitive nephrotic syndrome come of age: long-term outcome.

Authors:  Eva-Maria Rüth; Markus J Kemper; Ernst P Leumann; Guido F Laube; Thomas J Neuhaus
Journal:  J Pediatr       Date:  2005-08       Impact factor: 4.406

6.  Prospective, controlled trial of cyclophosphamide therapy in children with nephrotic syndrome. Report of the International study of Kidney Disease in Children.

Authors: 
Journal:  Lancet       Date:  1974-08-24       Impact factor: 79.321

7.  Long-term outcome of primary nephrotic syndrome.

Authors:  O Koskimies; J Vilska; J Rapola; N Hallman
Journal:  Arch Dis Child       Date:  1982-07       Impact factor: 3.791

8.  Long-term outcome for children with minimal-change nephrotic syndrome.

Authors:  R S Trompeter; B W Lloyd; J Hicks; R H White; J S Cameron
Journal:  Lancet       Date:  1985-02-16       Impact factor: 79.321

9.  The primary nephrotic syndrome in children. Identification of patients with minimal change nephrotic syndrome from initial response to prednisone. A report of the International Study of Kidney Disease in Children.

Authors: 
Journal:  J Pediatr       Date:  1981-04       Impact factor: 4.406

10.  A multicenter randomized trial indicates initial prednisolone treatment for childhood nephrotic syndrome for two months is not inferior to six-month treatment.

Authors:  Norishige Yoshikawa; Koichi Nakanishi; Mayumi Sako; Mari S Oba; Rintaro Mori; Erika Ota; Kenji Ishikura; Hiroshi Hataya; Masataka Honda; Shuichi Ito; Yuko Shima; Hiroshi Kaito; Kandai Nozu; Hidefumi Nakamura; Takashi Igarashi; Yasuo Ohashi; Kazumoto Iijima
Journal:  Kidney Int       Date:  2014-07-23       Impact factor: 10.612

View more
  5 in total

1.  Long-term obesity prevalence and linear growth in children with idiopathic nephrotic syndrome: is normal growth and weight control possible with steroid-sparing drugs and low-dose steroids for relapses?

Authors:  Nilüfer Göknar; Hazel Webb; Aoife Waters; Kjell Tullus
Journal:  Pediatr Nephrol       Date:  2021-11-12       Impact factor: 3.651

Review 2.  IPNA clinical practice recommendations for the diagnosis and management of children with steroid-sensitive nephrotic syndrome.

Authors:  Agnes Trautmann; Olivia Boyer; Elisabeth Hodson; Arvind Bagga; Debbie S Gipson; Susan Samuel; Jack Wetzels; Khalid Alhasan; Sushmita Banerjee; Rajendra Bhimma; Melvin Bonilla-Felix; Francisco Cano; Martin Christian; Deirdre Hahn; Hee Gyung Kang; Koichi Nakanishi; Hesham Safouh; Howard Trachtman; Hong Xu; Wendy Cook; Marina Vivarelli; Dieter Haffner
Journal:  Pediatr Nephrol       Date:  2022-10-21       Impact factor: 3.651

3.  Lipoproteins and cholesterol homeostasis in paediatric nephrotic syndrome patients.

Authors:  Yonas Mulat Simachew; Tamara Antonić; Tamara Gojković; Sandra Vladimirov; Marija Mihajlović; Sanja Vujčić; Gordana Miloševski-Lomić; Jelena Vekić; Aleksandra Zeljković; Vesna Spasojević-Kalimanovska; Amira Peco-Antić; Dušan Paripović; Aleksandra Stefanović
Journal:  Biochem Med (Zagreb)       Date:  2022-06-15       Impact factor: 2.515

Review 4.  Podocytopathies.

Authors:  Jeffrey B Kopp; Hans-Joachim Anders; Katalin Susztak; Manuel A Podestà; Giuseppe Remuzzi; Friedhelm Hildebrandt; Paola Romagnani
Journal:  Nat Rev Dis Primers       Date:  2020-08-13       Impact factor: 52.329

Review 5.  Pediatric idiopathic steroid-sensitive nephrotic syndrome: diagnosis and therapy -short version of the updated German best practice guideline (S2e) - AWMF register no. 166-001, 6/2020.

Authors:  Rasmus Ehren; Marcus R Benz; Paul T Brinkkötter; Jörg Dötsch; Wolfgang R Eberl; Jutta Gellermann; Peter F Hoyer; Isabelle Jordans; Clemens Kamrath; Markus J Kemper; Kay Latta; Dominik Müller; Jun Oh; Burkhard Tönshoff; Stefanie Weber; Lutz T Weber
Journal:  Pediatr Nephrol       Date:  2021-06-06       Impact factor: 3.714

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.